A U.S. government watchdog found that Medicare drug plans improperly authorized thousands of prescriptions for certain powerful opioids over a recent four-year period, a failure that cost taxpayers $86 million as the opioid crisis was raging across the country.
Between July 2015 and December 2019, Medicare Part D plans covered more than 7,500 prescriptions for so-called TIRF opioid painkillers, which contain fentanyl and are administered through the nose or mouth. The opioids were approved by U.S. regulators for managing breakthrough cancer pain, which is a sudden increase in pain beyond the usual chronic suffering felt by cancer patients.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
